# Multimodal Deep Learning for Postoperative Liver Cancer Risk Stratification and Intervention

> **NCT07282184** · PHASE1,PHASE2 · RECRUITING · sponsor: **Tongji Hospital** · enrollment: 144 (estimated)

## Conditions studied

- Hepotacellular Carcinoma

## Interventions

- **COMBINATION_PRODUCT:** Neoadjuvant HAIC + Lenvatinib + PD-1 Inhibitor
- **PROCEDURE:** Curative Liver Resection
- **OTHER:** Multimodal AI Risk Stratification

## Key facts

- **NCT ID:** NCT07282184
- **Lead sponsor:** Tongji Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-10-26
- **Primary completion:** 2027-06-30
- **Final completion:** 2028-06-30
- **Target enrollment:** 144 (ESTIMATED)
- **Last updated:** 2025-12-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07282184

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07282184, "Multimodal Deep Learning for Postoperative Liver Cancer Risk Stratification and Intervention". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07282184. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*